{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:49:19Z","timestamp":1795045759848,"version":"4.10.2"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.clineuro.2025.109011","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T11:50:00Z","timestamp":1749469800000},"page":"109011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Emergent role of complement inhibitors in myasthenic crisis: Understanding why, when and how"],"prefix":"10.1016","volume":"256","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7862-6743","authenticated-orcid":false,"given":"Elena","family":"Rossini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Morino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Garibaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Tufano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lauletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Forcina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Fionda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.clineuro.2025.109011_bib1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.clineuro.2025.109011_bib2","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1002\/eji.1830220939","article-title":"Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor","volume":"22","author":"Loutrari","year":"1992","journal-title":"Eur. J. Immunol."},{"issue":"6","key":"10.1016\/j.clineuro.2025.109011_bib3","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00401-020-02147-5","article-title":"Complement deposition at the neuromuscular junction in seronegative myasthenia gravis","volume":"139","author":"Hoffmann","year":"2020","journal-title":"Acta Neuropathol."},{"issue":"1","key":"10.1016\/j.clineuro.2025.109011_bib4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/1941875210382918","article-title":"Myasthenic crisis","volume":"1","author":"Wendell","year":"2011","journal-title":"Neurohospitalist"},{"issue":"6","key":"10.1016\/j.clineuro.2025.109011_bib5","first-page":"789","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis","volume":"41","author":"Gajdos","year":"1997","journal-title":"Myasthenia Gravis Clin. Study Group. Ann. Neurol."},{"issue":"2","key":"10.1016\/j.clineuro.2025.109011_bib6","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1002\/mus.26124","article-title":"Eculizumab in refractory myasthenic crisis","volume":"58","author":"Yeo","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clineuro.2025.109011_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420904207","article-title":"Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis","volume":"13","author":"Oyama","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"9","key":"10.1016\/j.clineuro.2025.109011_bib8","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1007\/s00415-021-10428-6","article-title":"Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19","volume":"268","author":"Hofstadt-van Oy","year":"2021","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.clineuro.2025.109011_bib9","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mus.27326","article-title":"The use of eculizumab in ventilator-dependent myasthenia gravis patients","volume":"64","author":"Usman","year":"2021","journal-title":"Muscle Nerve"},{"issue":"11","key":"10.1016\/j.clineuro.2025.109011_bib10","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1007\/s00415-022-11222-8","article-title":"Eculizumab as a fast-acting rescue therapy in a refractory myasthenic crisis: a case report","volume":"269","author":"Strano","year":"2022","journal-title":"J. Neurol."},{"issue":"10","key":"10.1016\/j.clineuro.2025.109011_bib11","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1007\/s10072-023-06900-y","article-title":"Starting eculizumab as rescue therapy in refractory myasthenic crisis","volume":"44","author":"Vinciguerra","year":"2023","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.clineuro.2025.109011_bib12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/muscles3010005","article-title":"Eculizumab as additional rescue therapy in myasthenic crisis","volume":"3","author":"Crescenzo","year":"2024","journal-title":"Muscles"},{"key":"10.1016\/j.clineuro.2025.109011_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241261602","article-title":"The safety and efficacy profile of eculizumab in myasthenic crisis: a prospective small case series","volume":"17","author":"Song","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clineuro.2025.109011_bib14","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241301361","article-title":"Complement inhibition in seropositive generalized myasthenia gravis as rescue therapy in impending and effective treatment in frequently recurring impending myasthenic crisis-a case series","volume":"17","author":"Menacher","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clineuro.2025.109011_bib15","doi-asserted-by":"crossref","DOI":"10.1007\/s10072-025-08128-4","article-title":"Prominent and fast response to eculizumab in myasthenic crisis: the potential as rescue therapy in refractory myasthenia gravis","author":"Messina","year":"2025","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.clineuro.2025.109011_bib16","doi-asserted-by":"crossref","DOI":"10.1007\/s12028-025-02237-w","article-title":"Eculizumab as a rescue therapy in prolonged myasthenic crisis in the intensive care unit: a case series","author":"Durmus","year":"2025","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.clineuro.2025.109011_bib17","doi-asserted-by":"crossref","DOI":"10.1007\/s12028-025-02272-7","article-title":"Eculizumab as treatment in refractory impeding and myasthenic crisis: a case series","author":"Erra","year":"2025","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.clineuro.2025.109011_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/25785826.2025.2500698","article-title":"Rapid response of eculizumab: a rescue therapy for ventilator-dependent refractory myasthenic crisis","author":"Takenobu","year":"2025","journal-title":"Immunol. Med."},{"issue":"7","key":"10.1016\/j.clineuro.2025.109011_bib19","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1007\/s00415-020-09770-y","article-title":"Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab","volume":"267","author":"Vissing","year":"2020","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.clineuro.2025.109011_bib20","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.nurt.2008.08.011","article-title":"Current and future standards in treatment of myasthenia gravis","volume":"5","author":"Gold","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.clineuro.2025.109011_bib21","article-title":"Efgartigimod as rescue medication in a patient with therapy-refractory myasthenic crisis","volume":"2024","author":"Alhaj Omar","year":"2024","journal-title":"Case Rep. Neurol. Med."},{"key":"10.1016\/j.clineuro.2025.109011_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1321058","article-title":"Case report: recovery from refractory myasthenic crisis to minimal symptom expression after add-on treatment with efgartigimod","volume":"15","author":"Watanabe","year":"2024","journal-title":"Front Neurol."},{"issue":"11","key":"10.1016\/j.clineuro.2025.109011_bib23","article-title":"Successful control of myasthenic crisis after the introduction of ravulizumab in myasthenia gravis: a case report","volume":"16","author":"Uchi","year":"2024","journal-title":"Cureus"},{"issue":"12","key":"10.1016\/j.clineuro.2025.109011_bib24","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clineuro.2025.109011_bib25","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-024-12588-7","article-title":"A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients","author":"Pane","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.clineuro.2025.109011_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.696385","article-title":"Eculizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis","volume":"12","author":"Monteleone","year":"2021","journal-title":"Front. Neurol."},{"issue":"3","key":"10.1016\/j.clineuro.2025.109011_bib27","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s13311-022-01181-3","article-title":"Antibody therapies in autoimmune neuromuscular junction disorders: approach to myasthenic crisis and chronic management","volume":"19","author":"Vanoli","year":"2022","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.clineuro.2025.109011_bib28","first-page":"100","article-title":"Neuromusclar junction and myasthenic crisis","volume":"102","author":"Mayer","year":"1977","journal-title":"Trans. Am. Neurol. Assoc."},{"issue":"8","key":"10.1016\/j.clineuro.2025.109011_bib29","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00415-006-0235-7","article-title":"Comparative efficacy of low dose, daily versus alternate day plasma exchange in severe myasthenia gravis: a randomised trial","volume":"254","author":"Trikha","year":"2007","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.clineuro.2025.109011_bib30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/mus.27832","article-title":"Myasthenic crisis","volume":"68","author":"Claytor","year":"2023","journal-title":"Muscle Nerve"}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030384672500294X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030384672500294X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T06:01:49Z","timestamp":1753509709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030384672500294X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":30,"alternative-id":["S030384672500294X"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2025.109011","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emergent role of complement inhibitors in myasthenic crisis: Understanding why, when and how","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2025.109011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109011"}}